Qol Holdings Co., Ltd.
Stock Price Chart
2026/08/21 UpdatedPrice Trend
2026/08/21 UpdatedPrice & Trading Details
2026/08/21 UpdatedPRICE
TRADING
Analyst Recommendations 1 analysts
Updated 2026/08/01Earnings Calendar
Updated 2026/08/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2021/02/02 | ¥39.90 | ¥41.80 | +4.8% |
| 2020/08/05 | ¥30.32 | ¥5.94 | -80.4% |
| 2020/02/04 | ¥40.20 | ¥28.51 | -29.1% |
Shareholder Composition
Updated 2026/08/01Dividend History
Updated 2026/08/23| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥27 | -32.5% |
| 2025 | ¥40 | +25.0% |
| 2024 | ¥32 | 0.0% |
| 2023 | ¥32 | +10.3% |
| 2022 | ¥29 | - |
Financial Performance
2026/08/23 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥170,036M | ¥180,052M | ¥263,972M | ¥290,772M |
| Gross Profit | ¥23,504M | ¥23,249M | ¥39,056M | ¥40,902M |
| Operating Income | ¥9,495M | ¥8,324M | ¥13,465M | ¥14,812M |
| Pretax Income | ¥9,673M | ¥8,969M | ¥13,063M | ¥14,746M |
| Net Income | ¥5,656M | ¥4,880M | ¥5,164M | ¥7,408M |
| EPS | ¥152.96 | ¥131.11 | ¥137.97 | ¥197.35 |
| Operating Margin | 5.58% | 4.62% | 5.10% | 5.09% |
| Balance Sheet | ||||
| Total Assets | ¥101,905M | ¥117,779M | ¥159,669M | ¥158,116M |
| Total Equity | ¥48,807M | ¥52,789M | ¥57,122M | ¥57,451M |
| Total Liabilities | ¥53,098M | ¥64,990M | ¥102,547M | ¥100,665M |
| Cash | ¥18,770M | ¥27,282M | ¥26,727M | ¥21,401M |
| Interest-bearing Debt | ¥22,750M | ¥31,632M | ¥41,071M | ¥37,481M |
| Equity Ratio | 47.89% | 44.82% | 35.78% | 36.33% |
| D/E Ratio | 0.47 | 0.60 | 0.72 | 0.65 |
| Cash Flow | ||||
| Operating CF | ¥11,662M | ¥13,533M | ¥12,593M | ¥18,665M |
| Investing CF | -¥7,013M | -¥13,155M | -¥20,360M | -¥9,088M |
| Financing CF | -¥2,569M | ¥7,969M | ¥7,201M | -¥14,966M |
| Free CF | ¥7,152M | ¥11,219M | -¥9,333M | ¥10,611M |
| Efficiency | ||||
| ROE | 11.59% | 9.24% | 9.04% | 12.89% |
| ROA | 5.55% | 4.14% | 3.23% | 4.69% |
Latest IR Information
-
Matters Related to Controlling Shareholders, etc.
Medipal Holdings Corporation is the company's largest shareholder holding 23.1% of shares. Explains the independence of parent-subsidiary relationships and transaction conditions. Currently no transactions with related parties. Discloses transactions with consolidated subsidiary Medisecao, including pharmaceutical procurement and accounts payable.
Read more -
Reintroduction of Trust-Type Employee Stock Ownership Incentive Plan
Qual Holdings Inc. has reintroduced a trust-type employee stock ownership incentive plan aimed at enhancing long- to mid-term corporate value and entered into a trust agreement on June 26, 2026.
Read more -
Financial Summary [Japanese Standards] for the Fiscal Year Ending March 2026 | Sales of 290.7 billion yen (YoY +8.3%)
For the fiscal year ending March 2026, sales reached 290.7 billion yen (YoY +8.3%), operating income was 14.8 billion yen, and net income was 7.4 billion yen, achieving both revenue growth and profit increase. Future outlook remains robust.
Read more -
Announcing increase in retained earnings dividends | May 2026
Quol Holdings has resolved to increase the year-end dividend for the fiscal year ending March 2026 to 27 yen per share, making the annual dividend 50 yen. The dividend increase reflects steady progress in performance and financial condition.
Read more
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥1,900
Rating Score: 3.00 (Based on 1 analysts)
※1=Strong Buy, 5=Strong Sell
Qol Holdings Delivers Strong Q1 Profit Surge and Confirms Higher Dividend Outlook - TipRanks ↗
Company Information
About
Qol Holdings Co., Ltd., together with its subsidiaries, engages in the pharmacy, BPO, and pharmaceutical businesses in Japan. The company operates dispensing pharmacies through one-on-one store opening based on one-on-one trust relationships with medical institutions. It also provides contract MR staffing; clinical research and development support services in the areas of food and pharmaceuticals; education and training services; and dispatch clinical research associates to support clinical trials. In addition, the company produce sales promotion materials for pharmaceuticals, as well as pamphlets and websites for medical institutions. Further, it engages in pharmaceutical manufacturing business; medical professional referral and dispatch business for the business areas, including pharmacist, medical clerical work, dispensing work, occupational physician, health nurse, nurse, and registered sales clerk; and business succession, health, and productivity management consulting business. The company was formerly known as Qol Co., Ltd. and changed its name to Qol Holdings Co., Ltd. in October 2018. The company was founded in 1992 and is headquartered in Tokyo, Japan.
